{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.7","upperLimit":"59","value":"42.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Subject reported improvement in symptom burden. The symptom burden will be measured according to the Lee cGVHD Symptom Scale. A change in \\>7 points on the Lee cGVHD Symptom Scale will be considered significant and relates to improvement in quality of life.\n\nA score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. A total summary score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.\n\nThere are 7 subscales (Skin, Energy, Lung, Eye, Nutrition, Mouth and Psychological) with ratings as follow: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely; with a lower values representing a better outcome.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects receive daily dose of 420 mg of Ibrutinib capsules","id":"OG000","title":"Phase 1b/Phase 2"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least 1 dose of ibrutinib at the recommended Phase 2 dose.","reportingStatus":"POSTED","timeFrame":"Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.","title":"Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Summary Score","type":"SECONDARY","unitOfMeasure":"percentage of participants"}